LEAD-452

N/A

Report date: 2023/08/02 17:09:59

Base Information

Drug NameLEAD-452
Drug Alias NameLEAD-452
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsUpdating
Therapy Area/IndicationsLung NeoplasmsHead and Neck NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLeadartis SL
China Registration ClassN/A

Develop Information

Active CompaniesLeadartis SL
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsHead and Neck NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A